Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating
Wedbush Adjusts TCR2 Therapeutics Price Target to $1.68 From $2.18, Maintains Neutral Rating
伏擊將 TCR2 治療價格目標價格從 2.18 美元調整至 1.68 美元，保持中性評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊